Trials
3 active
4 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL”In the company’s words, NCT04435990 on ClinicalTrials.gov
- Tested for
- Rhinoconjunctivitis (2 trials), Rhinitis, Allergic, Asthma, Allergic, Rhinitis, Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite
- Main trialPhase 3
- “A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.”In the company’s words, NCT04435990 on ClinicalTrials.gov
- Other names
- 10 · 30 · 3 · 9 · Allergen Immunotherapy Extract · ORALTEK
Other drugs for Rhinoconjunctivitis
- SHR-1819Hengrui · Phase 3
- StapokibartKeymed Biosciences Co.Ltd · Phase 3
- GR1802Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3
- Rupatifen FumarateFujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Phase 3
- EP-088_MM09Inmunotek S.L. · Phase 3
- DEP114EMS · Phase 3
Coming up2
- DecPhase 3 trial completes · ClinicalTrials.gov
- 27 Apr 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2026 | Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites | |
| Phase 3Recruiting | 27 Apr 2029 | Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df | |
| Phase 2/3Not yet recruiting | 1 Jun 2026 | Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract | |
| Phase 3Terminated | 9 Oct 2023 | Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026